Loss from operations was $908,465, compared to $1.29m for the comparable period in 2009.
For the nine months ended 30 September 2010 Catalyst posted a net loss of $3.28m, or $0.18 loss per diluted share, compared to$6.08m, or $0.43 loss per diluted share, for the year ago period.
Loss from operations was $3.29m, compared to $6.11m for the year ago period.
Catalyst CEO Patrick McEnany said that they were pleased with the recently reported positive results of their CPP-115 non-clinical program.
"We expect to begin the remaining non-clinical studies shortly to enable us to file an IND for CPP-115 by the middle of next year," McEnany said.
"Our CPP-109 US Phase II(b) cocaine trial in partnership with the National Institute on Drug Addiction (NIDA) and the US Veterans Administration is on track to commence in the fourth quarter of 2010.
"We are also excited by the addition of Silverman to our Scientific Advisory Board, and we expect that Silverman will help us explore new ways to maximise the potential of his discoveries that we in-licensed from Northwestern University last year."
Catalyst is a development-stage biopharmaceutical company focused on the development and commercialisation of prescription drugs targeting addiction and diseases of the central nervous system, such as epilepsy and neuropathic pain.